Abstract
Vaccines are the most efficient and economic tool to control and prevent infectious diseases in animals. First-generation vaccines; live attenuated and inactivated vaccines have been successful in producing healthy and productive livestock and controlling various infectious diseases. However, with increasing rate of emerging infections and the risk of resurgence of vaccine-controlled diseases, new vaccine strategies that are safer to use, and implicit both humoral and cellular immune responses need to be devised. Older generation vaccines are not capable of controlling the urgencies caused by newer epidemics and pandemics. The next-generation vaccine platforms such as recombinant subunit, virus-like particles, DNA, RNA, viral-vectored vaccines, etc., are capable of eliciting both humoral and cellular immune response, are cost-effective, and safer to use. With the emergence of COVID-19 pandemic, the field of medical science has excelled in producing fastest vaccines ever using next-generation vaccine technologies and reverse vaccinology. Similarly, the information of new generation vaccine platforms can be exploited in devising better vaccine development strategies in the field of veterinary science for controlling any such pandemics among animals in near future. This chapter elaborates upon various old generation and new generation vaccine platform technologies, reverse vaccinology, their role in veterinary vaccinology, and how these newer vaccine platforms can be deployed to design novel, efficient, and safer vaccines to control pandemics in animals, thereby also preventing zoonotic diseases under one-health program.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Agnandji ST, Lell B, Fernandes JF, Abossolo BP, Benjamin M, AL K et al (2012) A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med 367(24):2284–2295. https://doi.org/10.1056/nejmoa1208394
Aida V, Pliasas VC, Neasham PJ, North JF, McWhorter KL, Glover SR, Kyriakis CS (2021) Novel vaccine technologies in veterinary medicine: a herald to human medicine vaccines. Front Vet Sci 8(654289):1–20. https://doi.org/10.3389/fvets.2021.654289
Al-Halifa S, Gauthier L, Arpin D, Bourgault S, Archambault D (2019) Nanoparticle-based vaccines against respiratory viruses. Front Immunol 10(22):1–11. https://doi.org/10.3389/fimmu.2019.00022
Al-Kassmy J, Pedersen J, Kobinger G (2020) Vaccine candidates against coronavirus infections. Where does COVID-19 stand? Viruses 12(8):1–18. https://doi.org/10.3390/v12080861
Arimitsu H, Lee JC, Sakaguchi Y, Hayakawa Y, Hayashi M, Nakaura M, Takai H, Lin SN, Mukamoto M, Murphy T, Oguma K (2004) Vaccination with recombinant whole heavy chain fragments of clostridium botulinum type C and D neurotoxins. Clin Diagn Lab Immunol 11(3):496–502. https://doi.org/10.1128/CDLI.11.3.496-502.2004
Aurrecoechea C, Heiges M, Wang H, Wang Z, Fischer S, Rhodes P, Miller J, Kraemer E, Stoeckert CJ Jr, Roos DS, Kissinger JC (2007) ApiDB : integrated resources for the apicomplexan bioinformatics resource center. Nucleic Acids Res 35(Suppl. 1):427–430. https://doi.org/10.1093/nar/gkl880
Babiuk LA, Pontarollo R, Babiuk S, Loehr B, Littel-van VD, den Hurk S (2003) Induction of immune responses by DNA vaccines in large animals. Vaccine 21(7–8):649–658. https://doi.org/10.1016/S0264-410X(02)00574-1
Bagnoli F, Baudner B, Mishra RPN, Bartolini E, Fiaschi L, Mariotti P, Nardi-Dei V, Boucher P, Rappuoli R (2011) Designing the next generation of vaccines for global public health. OMICS: J Integr Biol 15(9):545–566. https://doi.org/10.1089/omi.2010.0127
Begg DJ, Dhungyel O, Naddi A, Dhand NK, Plain KM, de Silva K, Purdie AC, Whittington RJ (2019) The immunogenicity and tissue reactivity of Mycobacterium avium subsp paratuberculosis inactivated whole cell vaccine is dependent on the adjuvant used. Heliyon 5(6):e01911. https://doi.org/10.1016/j.heliyon.2019.e01911
Boigard H, Alimova A, Martin GR, Katz A, Gottlieb P, Galarza JM (2017) Zika virus-like particle (VLP) based vaccine. PLoS Negl Trop Dis 11(5):1–20. https://doi.org/10.1371/journal.pntd.0005608
Calina D, Docea AO, Petrakis D, Egorov AM, Ishmukhametov AA, Gabibov AG, Shtilman MI, Kostoff R, Carvalho F, Vinceti M, Spandidos DA, Tsatsakis A (2020) Towards effective COVID-19 vaccines: updates, perspectives and challenges (review). Int J Mol Med 46(1):3–16. https://doi.org/10.3892/ijmm.2020.4596
Calvo-Pinilla E, Marín-López A, Moreno S, Lorenzo G, Utrilla-Trigo S, Jiménez-Cabello L, Benavides J, Nogales A, Blasco R, Brun A, Ortego J (2020) A protective bivalent vaccine against Rift Valley fever and bluetongue. Npj Vaccines 5(1):1–12. https://doi.org/10.1038/s41541-020-00218-y
CDC (2018) Recombivax HB Hepatitis B Vaccine (Recombinant), pp 1–10. https://www.fda.gov/files/vaccines%2Cblood%26biologics/published/package-insert-recombivax-hb.pdf
Chackeriam B (2007) Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines 6(3):381–390. https://doi.org/10.1586/14760584.6.3.381
Chapman R, Rybicki EP (2019) Use of a novel enhanced DNA vaccine vector for preclinical virus vaccine investigation. Vaccine 7(2):1–12. https://doi.org/10.3390/vaccines7020050
Chauhan G, Madou MJ, Kalra S, Chopra V, Ghosh D, Martinez-Chapa SO (2020) Nanotechnology for COVID-19: therapeutics and vaccine research. ACS Nano 14(7):7760–7782. https://doi.org/10.1021/acsnano.0c04006
Cho HW, Howard CR, HW, L. (2002) Review of an inactivated vaccine against hantaviruses. Intervirology 45(4–6):328–333. https://doi.org/10.1159/000067925
Crisci E, Bárcena J, Montoya M (2012) Virus-like particles: the new frontier of vaccines for animal viral infections. Vet Immunol Immunopathol 148(3–4):211–225. https://doi.org/10.1016/j.vetimm.2012.04.026
Dai L, Gao GF (2021) Viral targets for vaccines against COVID-19. Nat Rev Immunol 21(2):73–82. https://doi.org/10.1038/s41577-020-00480-0
De Gregorio E, Rappuoli R (2014) From empiricism to rational design: a personal perspective of the evolution of vaccine development. Nat Rev Immunol 14(7):505–514. https://doi.org/10.1038/nri3694
Del Giudice G, Rappuoli R, Didierlaurent AM (2018) Correlates of adjuvanticity: a review on adjuvants in licensed vaccines. Semin Immunol 39:14–21. https://doi.org/10.1016/j.smim.2018.05.001
Deml L, Speth C, Dierich MP, Wolf H, Wagner R (2005) Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol 42(2):259–277. https://doi.org/10.1016/j.molimm.2004.06.028
Dhanasooraj D, Kumar RA, Mundayoor S (2016) Subunit protein vaccine delivery system for tuberculosis based on hepatitis B virus Core VLP (HBc-VLP) particles. Methods Mol Biol 1404:377–392. https://doi.org/10.1007/978-1-4939-3389-1_26
Dhanwani R, Ly H, Liang Y (2017) Recombinant tri-segmented Pichinde virus as a novel live viral vaccine platform. Methods Mol Biol 1581:169–179. https://doi.org/10.1007/978-1-4939-6869-5_10
Diamond MS, Pierson TC (2020) The challenges of vaccine development against a new virus during a pandemic. Cell Host Microbe 27(5)¸:699–703. https://doi.org/10.1016/j.chom.2020.04.021
Dintzis RZ (1992) Rational design of conjugate vaccines. Pediatr Res 32(4):376–385. https://doi.org/10.1203/00006450-199210000-00002
Dormont F, Brusini R, Cailleau C, Reynaud F, Reynaud F, Peramo A, Gendron A, Mougin J, Gaudin F, Gaudin F, Varna M, Couvreur P (2020) Squalene-based multidrug nanoparticles for improved mitigation of uncontrolled inflammation in rodents. Sci Adv 6(23):1–11. https://doi.org/10.1126/sciadv.aaz5466
El-Attar L, Oliver SL, Mackie A, Charpilienne A, Poncet D, Cohen J, Bridger JC (2009) Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease. Vaccine 27(24):3201–3208. https://doi.org/10.1016/j.vaccine.2009.03.043
Entrican G, Francis MJ (2022) Applications of platform technologies in veterinary vaccinology and the benefits for one health. Vaccine 40(20):2833–2840. https://doi.org/10.1016/j.vaccine.2022.03.059
Eshghi A, Cullen PA, Cowen L, Zuerner RL, Cameron CE (2009) Global proteome analysis of Leptospira interrogans. J Proteome Res 8(10):4564–4578. https://doi.org/10.1021/pr9004597
Esmaeilzadeh A, Elahi R (2021) Immunobiology and immunotherapy of COVID-19: a clinically updated overview. J Cell Physiol 236(4):2519–2543. https://doi.org/10.1002/jcp.30076
Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, Weiner DB (2011) Clinical applications of DNA vaccines: current progress. Clin Infect Dis 53(3):296–302. https://doi.org/10.1093/cid/cir334
Ferri M, Lloyd-Evans M (2021) The contribution of veterinary public health to the management of the COVID-19 pandemic from a one health perspective. One Health 12:100230. https://doi.org/10.1016/j.onehlt.2021.100230
Francis MJ (2018) Recent advances in vaccine technologies. Vet Clin North Am Small Anim Pract 48(2):231–241. https://doi.org/10.1016/j.cvsm.2017.10.002
Franco D, Liu W, Gardiner DF, Hahn BH, Ho DD (2011) CD40L-containing virus-like particle as a candidate HIV-1 vaccine targeting dendritic cells. J Acquir Immune Defic Syndr 56(5):393–400. https://doi.org/10.1097/QAI.0b013e31820b844e
Frederiksen LSF, Zhang Y, Foged C, Thakur A (2020) The long road toward COVID-19 herd immunity: vaccine platform technologies and mass immunization strategies. Front Immunol 11(1817):1–26. https://doi.org/10.3389/fimmu.2020.01817
Frietze KM, Peabody DS, Chackerian B (2016) Engineering virus-like particles as vaccine platforms. Curr Opin Virol 18:44–49. https://doi.org/10.1016/j.coviro.2016.03.001
Ghosh S, Nagar G (2014) Problem of ticks and tick-borne diseases in India with special emphasis on progress in tick control research: a review. J Vector Borne Dis 51(4):259–270
GlaxoSmithKline (1989) ENGERIX-B is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. For intramuscular administration. See Section 2.2 for subcutaneous administration in persons at risk of hemorrhage. Preparation for Administr. 1–16. https://www.fda.gov/media/119403/download
GlaxoSmithKline (2009) CERVARIX [Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, Recombinant] Suspension for Intramuscular injection. 1–28. https://www.fda.gov/media/78013/download
Grgacic EVL, Anderson DA (2006) Virus-like particles: Passport to immune recognition. Methods 40(1):60–65. https://doi.org/10.1016/j.ymeth.2006.07.018
Han Y, Král P (2020) Computational design of ACE2-based peptide inhibitors of SARS-CoV-2. ACS Nano 14(4):5143–5147. https://doi.org/10.1021/acsnano.0c02857
Han J, Zhao D, Li D, Wang X, Jin Z, Zhao K (2018) Polymer-based nanomaterials and applications for vaccines and drugs. Polymers 10(1):1–14. https://doi.org/10.3390/polym10010031
Hartwig DD, Oliveira TL, Seixas FK, Forster KM, Rizzi C, Hartleben CP, Mcbride AJA, Dellagostin OA (2010) High yield expression of leptospirosis vaccine candidates LigA and LipL32 in the methylotrophic yeast Pichia. Pastoris 9(98):1–7
Heinson AI, Woelk CH, Newell ML (2015) The promise of reverse vaccinology. Int Health 7(2):85–89. https://doi.org/10.1093/inthealth/ihv002
Hobernik D, Bros M (2018) DNA vaccines — how far from clinical use ? Figure 1:19(3605),1–28. https://doi.org/10.3390/ijms19113605
Hu CMJ, Chang WS, Fang ZS, Chen YT, Wang WL, Tsai HH, Chueh LL, Takano T, Hohdatsu T, Chen HW (2017) Nanoparticulate vacuolar ATPase blocker exhibits potent host-targeted antiviral activity against feline coronavirus. Sci Rep 7(1):1–11. https://doi.org/10.1038/s41598-017-13316-0
IPBES (2020) Workshop report on biodiversity and pandemics of the intergovernmental platform on biodiversity and ecosystem services. Daszak, P., Amuasi, J., das Neves, C. G., Hayman, D., Kuiken, T., Roche, B., Zambrana-Torrelio, C., Buss, P., Dundarova, H., Feferholtz, Y., Földvári, G., Igbinosa, E., Junglen, S., Liu, Q., Suzan, G., Uhart, M., Wannous, C., Woolaston, K., Mosig Reidl, P., O’Brien, K., Pascual, U., Stoett, P., Li, H., Ngo, H. T., IPBES secretariat, Bonn, Germany, DOI:https://doi.org/10.5281/zenodo.4147317
Jafari A, Danesh Pouya F, Niknam Z, Abdollahpour-Alitappeh M, Rezaei-Tavirani M, Rasmi Y (2022) Current advances and challenges in COVID-19 vaccine development: from conventional vaccines to next-generation vaccine platforms. Mol Biol Rep 49:4943. https://doi.org/10.1007/s11033-022-07132-7
Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z (2020) Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol 20(10):615–632. https://doi.org/10.1038/s41577-020-00434-6
Jorge S, Dellagostin OA (2017) The development of veterinary vaccines: a review of traditional methods and modern biotechnology approaches. Biotechnol Res Innov 1(1):6–13. https://doi.org/10.1016/j.biori.2017.10.001
Khan KH (2013) DNA vaccines: roles against diseases. Germs 3(1):26–35. https://doi.org/10.11599/germs.2013.1034
Kremer FS, Eslabão MR, Jorge S, Oliveira NR, Labonde J, Santos MNP, Monte LG, Grassmann AA, Cunha CEP, Forster KM, Moreno LZ, Moreno AM, Campos VF, McBride AJA, Pinto LS, Dellagostin OA (2016) Draft genome of the leptospira interrogans strains, acegua, RCA, prea, and capivara, obtained from wildlife maintenance hosts and infected domestic animals. Mem Inst Oswaldo Cruz 111(4):280–283. https://doi.org/10.1590/0074-02760160010
Kushnir N, Streatfield SJ, Yusibov V (2012) Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine 31(1):58–83. https://doi.org/10.1016/j.vaccine.2012.10.083
Leung AKC (2011) “Variolation” and vaccination in late imperial China. In: Pltokin SA (ed) History of vaccine development. Springer, pp 5–12. https://doi.org/10.1007/978-1-4419-1339-5
Li H, Li Y, Wang X, Hou Y, Hong X, Gong T, Zhang Z, Sun X (2017a) Rational design of polymeric hybrid micelles to overcome lymphatic and intracellular delivery barriers in cancer immunotherapy. Theranostics 7(18):4383. https://doi.org/10.7150/thno.20745
Li H, Shao S, Cai J, Burner D, Lu L, Chen Q, Minev B, Ma W (2017b) Artificial human antigen-presenting cells are superior to dendritic cells at inducing cytotoxic T-cell responses. Immunology 152(3):462–471. https://doi.org/10.1111/imm.12783
Maina TW, Grego EA, Boggiatto PM, Sacco RE, Narasimhan B, McGill JL (2020) Applications of Nanovaccines for disease prevention in cattle. Front Bioeng Biotechnol 8:1–20. https://doi.org/10.3389/fbioe.2020.608050
Meeusen ENT, Walker J, Peters A, Pastoret PP, Jungersen G (2007) Current status of veterinary vaccines. Clin Microbiol Rev 20(3):489–510. https://doi.org/10.1128/CMR.00005-07
Melnick JL (1978) Advantages and disadvantages of killed and live poliomyelitis vaccines. Bull World Health Organ 56(1):21–38
Mendonça SA, Lorincz R, Boucher P, Curiel DT (2021) Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. Npj Vaccines 6(1):97. https://doi.org/10.1038/s41541-021-00356-x
Merad M, Martin JC (2020) Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 20(6):355–362. https://doi.org/10.1038/s41577-020-0331-4
Merck&Co (2015) Package insert GARDASIL® [human papillomavirus Quadrivalent (types 6, 11, 16, and 18) vaccine, recombinant] suspension for intramuscular injection. Merck & Co, pp 1–28. https://www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf, https://www.fda.gov/files/vaccines,blood&biologics/published/Package-Insert%2D%2D-Gardasil.pdf
Mohsen MO, Zha L, Cabral-Miranda G, Bachmann MF (2017) Major findings and recent advances in virus–like particle (VLP)-based vaccines. Semin Immunol 34:123–132. https://doi.org/10.1016/j.smim.2017.08.014
Moon JJ, Suh H, Li AV, Ockenhouse CF, Yadava A, Irvine DJ (2012) Enhancing humoral responses to a malaria antigen with nanoparticle vaccines that expand T fh cells and promote germinal center induction. Proc Natl Acad Sci U S A 109(4):1080–1085. https://doi.org/10.1073/pnas.1112648109
Moreira C, da Cunha CEP, Moreira GMSG, Mendonça M, Salvarani FM, Moreira ÂN, Conceição FR (2016) Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D. Anaerobe 40:58–62. https://doi.org/10.1016/j.anaerobe.2016.05.012
Muhammad W, Zhai Z, Gao C (2020) Antiviral activity of nanomaterials against coronaviruses. Macromol Biosci 20(10):2000196. https://doi.org/10.1002/mabi.202000196
Murata K, Lechmann M, Qiao M, Gunji T, Altert HJ, Liang TJ (2003) Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc Natl Acad Sci U S A 100(11):6753–6758. https://doi.org/10.1073/pnas.1131929100
Naskalska A, Dabrowska A, Nowak P, Szczepanski A, Jasik K, Milewska A, Ochman M, Zeglen S, Rajfur Z, Pyrc K (2018) Novel coronavirus-like particles targeting cells lining the respiratory tract. PLoS One 13(9):1–21. https://doi.org/10.1371/journal.pone.0203489
Netland J, DeDiego ML, Zhao J, Fett C, Álvarez E, Nieto-Torres JL, Enjuanes L, Perlman S (2010) Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. Virology 399(1):120–128. https://doi.org/10.1016/j.virol.2010.01.004
Odir AD, Grassmann AA, Hartwig DD, Félix SR, Da Silva ÉF, McBride AJA (2011) Recombinant vaccines against leptospirosis. Hum Vaccin 7(11):1215–1224. https://doi.org/10.4161/hv.7.11.17944
Oliveira TL, Grassmann AA, Schuch RA, Neto ACPS, Mendonça M, Hartwig DD, McBride AJA, Dellagostin OA (2015) Evaluation of the leptospira interrogans outer membrane protein OmpL37 as a vaccine candidate. PLoS One 10(11):1–13. https://doi.org/10.1371/journal.pone.0142821
Overgaard NH, Frøsig TM, Jakobsen JT, Buus S, Andersen MH, Jungersen G (2017) Low antigen dose formulated in CAF09 adjuvant Favours a cytotoxic T-cell response following intraperitoneal immunization in Göttingen minipigs. Vaccine 35(42):5629–5636. https://doi.org/10.1016/j.vaccine.2017.08.057
Paillot R, Grimmett H, Elton D, Daly JM (2008) Protection, systemic IFNγ, and antibody responses induced by an ISCOM-based vaccine against a recent equine influenza virus in its natural host. Vet Res 39(3):21. https://doi.org/10.1051/vetres:2007062
Paliard X, Liu Y, Wagner R, Wolf H, Baenziger J, Walker CM (2000) Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after Administration of a Virus-like Particle Vaccine in rhesus macaques. AIDS Res Hum Retrovir 16(3):273–282. https://doi.org/10.1089/088922200309368
Panicali D, Paoletti E (1982) Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A 79(16):4927–4931. https://doi.org/10.1073/pnas.79.16.4927
Pati R, Shevtsov M, Sonawane A (2018) Nanoparticle vaccines against infectious diseases. Front Immunol 9:2224. https://doi.org/10.3389/fimmu.2018.02224
Pillay S, Shephard EG, Meyers AE, Williamson AL, Rybicki EP (2010) HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice. J Immune Based Ther Vaccines 8(7):2–7. https://doi.org/10.1186/1476-8518-8-7
Pimentel TAPF, Yan Z, Jeffers SA, Holmes KV, Hodges RS, Burkhard P (2009) Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. Chem Biol Drug Des 73(1):53–61. https://doi.org/10.1111/j.1747-0285.2008.00746.x
Pizza M, Scarlato V, Masignani V, Giuliani M, Aricò B, Comanducci M, Jennings G, Baldi L, Bartolini E, Capecchi B, Galeotti C, Luzzi E, Manetti R, Marchetti E, Mora M, Nuti S, Ratti G, Santini L, Savino S, Rappuoli R (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287(5459):1816–1820. https://doi.org/10.1126/science.287.5459.1816
Plotkin S (2014) History of vaccination. Proc Natl Acad Sci U S A 111(34):12283–12287. https://doi.org/10.1073/pnas.1400472111
Rappuoli R (2001) Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19(17–19):2688–2691. https://doi.org/10.1016/S0264-410X(00)00554-5
Rappuoli R, Pizza M, Del Giudice G, De Gregorio E (2014) Vaccines, new opportunities for a new society. Proc Natl Acad Sci U S A 111(34):12288–12293. https://doi.org/10.1073/pnas.1402981111
Ravipaty S, Reilly JP (2010) Comprehensive characterization of methicillin-resistant Staphylococcus aureus subsp. aureus COL secretome by two-dimensional liquid chromatography and mass spectrometry. Mol Cell Proteomics 9(9):1898–1919. https://doi.org/10.1074/mcp.M900494-MCP200
Riedel S (2005) Edward Jenner and the history of smallpox and vaccination. Bayl Univ Med Cent Proc 18(1):21–25. https://doi.org/10.1080/08998280.2005.11928028
Rizzi C, Bianco MV, Blanco FC, Soria M, Gravisaco MJ, Montenegro V, Vagnoni L, Buddle B, Garbaccio S, Delgado F, Leal KS, Cataldi AA, Dellagostin OA, Bigi F (2012) Vaccination with a BCG strain overexpressing Ag85B protects cattle against Mycobacterium bovis challenge. PLoS One 7(12):1–10. https://doi.org/10.1371/journal.pone.0051396
Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, Baum A, Pascal K, Quandt J, Maurus D, Brachtendorf S, Lörks V, Sikorski J, Hilker R, Becker D, Eller AK, Grützner J, Boesler C, Rosenbaum C, Türeci Ö et al (2020) COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586(7830):594–599. https://doi.org/10.1038/s41586-020-2814-7
Salian VS, Wright JA, Vedell PT, Nair S, Li C, Kandimalla M, Tang X, Carmona Porquera EM, Kalari KR, Kandimalla KK (2021) COVID-19 transmission, current treatment, and future therapeutic strategies. Mol Pharm 18(3):754–771. https://doi.org/10.1021/acs.molpharmaceut.0c00608
Schirmbeck R, Böhm W, Reimann J (1996) Virus-like particles induce MHC class I-restricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology 39(1–2):111–119. https://doi.org/10.1159/000150482
Seib KL, Zhao X, Rappuoli R (2012) Developing vaccines in the era of genomics: a decade of reverse vaccinology. Clin Microbiol Infect 18(SUPPL. 5):109–116. https://doi.org/10.1111/j.1469-0691.2012.03939.x
Sekimukai H, Iwata-Yoshikawa N, Fukushi S, Tani H, Kataoka M, Suzuki T, Hasegawa H, Niikura K, Arai K, Nagata N (2020) Gold nanoparticle-adjuvanted S protein induces a strong antigen-specific IgG response against severe acute respiratory syndrome-related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs. Microbiol Immunol 64(1):33–51. https://doi.org/10.1111/1348-0421.12754
Shams H (2005) Recent developments in veterinary vaccinology. Vet J 170(3):289–299. https://doi.org/10.1016/j.tvjl.2004.07.004
Simionatto S, Marchioro SB, Galli V, Hartwig DD, Carlessi RM, Munari FM, Laurino JP, Conceição FR, Dellagostin OA (2010) Cloning and purification of recombinant proteins of mycoplasma hyopneumoniae expressed in Escherichia coli. Protein Expr Purif 69(2):132–136. https://doi.org/10.1016/j.pep.2009.09.001
Soema PC, Kompier R, Amorij JP, Kersten GFA (2015) Current and next generation influenza vaccines: formulation and production strategies. Eur J Pharm Biopharm 94:251–263. https://doi.org/10.1016/j.ejpb.2015.05.023
Song JM, Wang BZ, Park KM, van Rooijen N, Quan FS, Kim MC, Jin HT, Pekosz A, Compans RW, Kang SM (2011) Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 6(1):e14538. https://doi.org/10.1371/journal.pone.0014538
Spickler AR, Roth JA (2003) Adjuvants in veterinary vaccines: modes of action and adverse effects. J Vet Intern Med 17(3):273–281. https://doi.org/10.1111/j.1939-1676.2003.tb02448.x
Staroverov SA, Vidyasheva IV, Gabalov KP, Vasilenko OA, Laskavyi VN, Dykman LA (2011) Immunostimulatory effect of gold nanoparticles conjugated with transmissible gastroenteritis virus. Bull Exp Biol Med 151(4):436–439. https://doi.org/10.1007/s10517-011-1350-8
Suarez DL (2012) DIVA vaccination strategies for avian influenza virus. Avian Dis 56(4s1):836–844. https://doi.org/10.1637/10207-041512-Review.1
Sun SH, Chen Q, Gu HJ, Yang G, Wang YX, Huang XY, Liu SS, Zhang NN, Li XF, Xiong R, Guo Y, Deng YQ, Huang WJ, Liu Q, Liu QM, Shen YL, Zhou Y, Yang X, Zhao TY, Wang YC et al (2020) A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe 28(1):124–133.e4. https://doi.org/10.1016/j.chom.2020.05.020
Tiwari A, Gautam A, Bhat S, Malik YS (2020) Advances and applications of vectored vaccines in animal diseases. In: Khurana SMP, Malik YS, Barh D, Azevedo V (eds) Genomics and biotechnological advances in veterinary, poultry, and fisheries. Academic press (Elsevier), pp 361–380. https://doi.org/10.1016/B978-0-12-816352-8.00015-1
Tizard IR (2020) Adjuvants and Adjuvanticity. In: Vaccines for Veterinarians, vol ed.1, pp 75–86. https://doi.org/10.1016/B978-0-323-68299-2.00016-2
van Gelder P, Makoschey B (2012) Production of viral vaccines for veterinary use. Berl Munch Tierarztl Wochenschr 125(3–4):103–109. https://doi.org/10.2376/0005-9366-125-103
van Riel D, de Wit E (2020) Next-generation vaccine platforms for COVID-19. Nat Mater 19(8):810–812. https://doi.org/10.1038/s41563-020-0746-0
Volz A, Sutter G (2017) Modified vaccinia virus Ankara: history, value in basic research, and current perspectives for vaccine development. In: Advances in virus research, vol 97, 1st edn. Elsevier Inc, p 97. https://doi.org/10.1016/bs.aivir.2016.07.001
Wang J, Peng Y, Xu H, Cui Z, Williams RO (2020) The COVID-19 vaccine race: challenges and opportunities in vaccine formulation. AAPS PharmSciTech 21(6):225. https://doi.org/10.1208/s12249-020-01744-7
Win SJ, Ward VK, Dunbar PR, Young SL, Baird MA (2011) Cross-presentation of epitopes on virus-like particles via the MHC I receptor recycling pathway. Immunol Cell Biol 89(6):681–688. https://doi.org/10.1038/icb.2010.161
Ye S, Shao K, Li Z, Guo N, Zuo Y, Li Q, Lu Z, Chen L, He Q, Han H (2015) Antiviral activity of graphene oxide: how sharp edged structure and charge matter. ACS Appl Mater Interfaces 7(38):21578–21579. https://doi.org/10.1021/acsami.5b06876
Zhao L, Seth A, Wibowo N, Zhao CX, Mitter N, Yu C, Middelberg APJ (2014) Nanoparticle vaccines. Vaccine 32(3):327–337. https://doi.org/10.1016/j.vaccine.2013.11.069
Zhou H, Guo L, Wang M, Qu J, Zhao Z, Wang J, Hung T (2011) Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice. Virol J 8:2–9. https://doi.org/10.1186/1743-422X-8-3
Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F (2020) Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell. Discovery 6(1):14. https://doi.org/10.1038/s41421-020-0153-3
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Gautam, A., Gautam, H., Sharma, A., Malik, Y.S. (2023). Harnessing Knowledge from COVID-19 Scenario for New Generation Vaccine Development to Control Pandemics in Animals. In: Mukhopadhyay, C.S., Choudhary, R.K., Panwar, H., Malik, Y.S. (eds) Biotechnological Interventions Augmenting Livestock Health and Production. Livestock Diseases and Management. Springer, Singapore. https://doi.org/10.1007/978-981-99-2209-3_14
Download citation
DOI: https://doi.org/10.1007/978-981-99-2209-3_14
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-99-2208-6
Online ISBN: 978-981-99-2209-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)